Related references
Note: Only part of the references are listed.Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis
David Charles et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2022)
Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review
Elliot Israel et al.
JOURNAL OF ASTHMA (2022)
Benralizumab in Real Life
J. C. Miralles Lopez et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2021)
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
Christian Domingo Ribas et al.
DRUGS (2021)
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
Tim W. Harrison et al.
LANCET RESPIRATORY MEDICINE (2021)
Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
Giulia Scioscia et al.
FRONTIERS IN PHARMACOLOGY (2021)
Real world effectiveness of benralizumab on respiratory function and asthma control
Francesco Menzella et al.
MULTIDISCIPLINARY RESPIRATORY MEDICINE (2021)
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
Angelantonio Maglio et al.
BIOMEDICINES (2021)
Mepolizumab for severe eosinophilic asthma - A one-year real life Portuguese study
R. Bras et al.
PULMONOLOGY (2021)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Ioana Agache et al.
ALLERGY (2020)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Ioana Agache et al.
ALLERGY (2020)
Mepolizumab effectiveness and identification of super-responders in severe asthma
Erin S. Harvey et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Real-World Effectiveness and the Characteristics of a Super-Responder to Mepolizumab in Severe Eosinophilic Asthma
Joanne E. Kavanagh et al.
CHEST (2020)
Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
David J. Jackson et al.
DRUG SAFETY (2020)
Benralizumab: an updated treatment of eosinophilic asthma
Breda Cushen et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
The management of severe asthma in 2020
Andreanne Cote et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data
Andreas Renner et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
Claudia Crimi et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2020)
Biomarkers for severe eosinophilic asthma
Steven W. Yancey et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma
Hector Ortega et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
EAACI position statement on asthma exacerbations and severe asthma
A. Custovic et al.
ALLERGY (2013)
Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry
Liam G. Heaney et al.
THORAX (2010)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?
Justin Travers et al.
THORAX (2007)
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
Wendy C. Moore et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Asthma exacerbations • 4:: Prevention
J. M. FitzGerald et al.
THORAX (2006)
An international observational prospective study to determine the Cost Of Asthma eXacerbations (COAX)
S Lane et al.
RESPIRATORY MEDICINE (2006)
Risk factors of frequent exacerbations in difficult-to-treat asthma
A ten Brinke et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma
B Abraham et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics
A Menzies-Gow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark
P Vestergaard et al.
JOURNAL OF INTERNAL MEDICINE (2003)
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
RH Green et al.
LANCET (2002)
Mechanisms involved in the side effects of glucocorticoids
H Schäcke et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
MJ Leckie et al.
LANCET (2000)
Asthma - From bronchoconstriction to airways inflammation and remodeling
J Bousquet et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Risk factors and costs associated with an asthma attack
G Hoskins et al.
THORAX (2000)
Changes in sputum eosinophils predict less of asthma control
A Jatakanon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
